Altered levels of cytokine, T- and B-lymphocytes, and PD-1 expression rates in drug-naïve schizophrenia patients with acute phase

[1]  K. Walder,et al.  Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. , 2023, The lancet. Psychiatry.

[2]  M. Banerjee,et al.  Contribution from MHC-Mediated Risk in Schizophrenia Can Reflect a More Ethnic-Specific Genetic and Comorbid Background , 2022, Cells.

[3]  John A. Williams,et al.  Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders , 2022, JAMA psychiatry.

[4]  C. Kummer,et al.  Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology , 2021, The EMBO journal.

[5]  A. Hutloff,et al.  T Cell/B Cell Interactions in the Establishment of Protective Immunity , 2021, Vaccines.

[6]  R. McIntyre,et al.  Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis , 2021, Neuroscience & Biobehavioral Reviews.

[7]  S. Ovsepian,et al.  Endogenous antagonists of N‐methyl‐d‐aspartate receptor in schizophrenia , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[8]  T. Fukuwatari.  Possibility of Amino Acid Treatment to Prevent the Psychiatric Disorders via Modulation of the Production of Tryptophan Metabolite Kynurenic Acid , 2020, Nutrients.

[9]  C. Burger,et al.  The Role of PD-1 in Acute and Chronic Infection , 2020, Frontiers in Immunology.

[10]  O. Howes,et al.  Schizophrenia-An Overview. , 2020, JAMA psychiatry.

[11]  K. Nakazawa,et al.  The origin of NMDA receptor hypofunction in schizophrenia. , 2020, Pharmacology & therapeutics.

[12]  A. Sawa,et al.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives , 2019, Neurobiology of Disease.

[13]  P. Buckley.  Neuroinflammation and Schizophrenia , 2019, Current Psychiatry Reports.

[14]  J. Leza,et al.  Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. , 2018, Schizophrenia bulletin.

[15]  L. Walker,et al.  T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship , 2018, Front. Immunol..

[16]  N. Müller.  Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations , 2018, Schizophrenia bulletin.

[17]  C. Carter,et al.  Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms , 2018, Journal of Neuroinflammation.

[18]  V. Apostolopoulos,et al.  PD-1/PD-L1 in disease. , 2018, Immunotherapy.

[19]  B. Horta,et al.  Inflammatory Biomarkers and Risk of Schizophrenia , 2017, JAMA psychiatry.

[20]  E. Severance,et al.  The microbiome, immunity, and schizophrenia and bipolar disorder , 2017, Brain, Behavior, and Immunity.

[21]  J. McGrath,et al.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. , 2017, The lancet. Psychiatry.

[22]  Shao-hua Hu,et al.  Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study , 2017, Scientific Reports.

[23]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[24]  A. Vita,et al.  Schizophrenia , 2016, The Lancet.

[25]  J. Smoller,et al.  A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder , 2015, Molecular Psychiatry.

[26]  R. Kefford,et al.  Immune checkpoint inhibitors in melanoma. , 2015, Melanoma management.

[27]  M. Debnath.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment , 2015, Journal of Neuroimmune Pharmacology.

[28]  Peter B. Jones,et al.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.

[29]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[30]  P. Kochunov,et al.  Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. , 2014, JAMA psychiatry.

[31]  A. Corvin,et al.  Genome-wide Association Studies: Findings at the Major Histocompatibility Complex Locus in Psychosis , 2014, Biological Psychiatry.

[32]  Károly Mirnics,et al.  Immune System Disturbances in Schizophrenia , 2014, Biological Psychiatry.

[33]  Yong-Ku Kim,et al.  The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[34]  P. Buckley,et al.  Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects , 2013, Biological Psychiatry.

[35]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[36]  H. Meltzer,et al.  Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: Relationship to plasma cortisol concentration , 2011, Psychiatry Research.

[37]  M. Schwarz,et al.  T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment , 2007, Psychiatry Research.

[38]  J. McGrath,et al.  A Systematic Review of the Prevalence of Schizophrenia , 2005, PLoS medicine.

[39]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[40]  D. Wakefield,et al.  Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder , 1996, Psychiatry Research.

[41]  R. S. Smith,et al.  The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. , 1995, Medical hypotheses.